APS.CA Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Aptose Biosciences, Inc.

Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical

8 days ago - By: Aptose Biosciences, Inc.

Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical

14 days ago - By: Aptose Biosciences, Inc.

Aptose Reports Third Quarter 2025 Results

14 days ago - By: Aptose Biosciences, Inc.

Aptose Reports Third Quarter 2025 Results

4 months ago - By: Aptose Biosciences, Inc.

Aptose Reports Second Quarter 2025 Results

5 months ago - By: Aptose Biosciences, Inc.

Aptose Upgraded to Trade on OTCQB Market

5 months ago - By: Aptose Biosciences, Inc.

Aptose Announces Deferral of Interest Payment

24 days ago - By: Aptose Biosciences, Inc.

Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting

a month ago - By: Aptose Biosciences, Inc.

Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML

a month ago - By: Aptose Biosciences, Inc.

Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML

5 months ago - By: Aptose Biosciences, Inc.

Aptose Provides Corporate Updates

2 months ago - By: Aptose Biosciences, Inc.

Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML

2 months ago - By: Aptose Biosciences, Inc.

Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML

3 months ago - By: Aptose Biosciences, Inc.

Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor

3 months ago - By: Aptose Biosciences, Inc.

Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor

3 months ago - By: Aptose Biosciences, Inc.

Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial

3 months ago - By: Aptose Biosciences, Inc.

Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial

4 months ago - By: Aptose Biosciences, Inc.

Aptose Reports Second Quarter 2025 Results

4 months ago - By: Aptose Biosciences, Inc.

Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy

4 months ago - By: Aptose Biosciences, Inc.

Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy

4 months ago - By: Aptose Biosciences, Inc.

Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders

4 months ago - By: Aptose Biosciences, Inc.

Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders

4 months ago - By: Aptose Biosciences, Inc.

Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML

4 months ago - By: Aptose Biosciences, Inc.

Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML

5 months ago - By: Aptose Biosciences, Inc.

Aptose Upgraded to Trade on OTCQB Market

5 months ago - By: Aptose Biosciences, Inc.

Aptose Announces Deferral of Interest Payment

5 months ago - By: Aptose Biosciences, Inc.

Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML

5 months ago - By: Aptose Biosciences, Inc.

Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML

5 months ago - By: Aptose Biosciences, Inc.

Aptose Provides Corporate Updates

6 months ago - By: Aptose Biosciences, Inc.

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

6 months ago - By: Aptose Biosciences, Inc.

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

6 months ago - By: Aptose Biosciences, Inc.

Aptose Announces Results from Annual and Special Meeting of Shareholders

6 months ago - By: Aptose Biosciences, Inc.

Aptose Announces Results from Annual and Special Meeting of Shareholders

6 months ago - By: Aptose Biosciences, Inc.

Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee

6 months ago - By: Aptose Biosciences, Inc.

Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee

7 months ago - By: Aptose Biosciences, Inc.

Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

7 months ago - By: Aptose Biosciences, Inc.

Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

7 months ago - By: Aptose Biosciences, Inc.

Aptose Reports First Quarter 2025 Results

7 months ago - By: Aptose Biosciences, Inc.

Aptose Reports First Quarter 2025 Results

7 months ago - By: Aptose Biosciences, Inc. - Mentions: APTO

Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial

APTOSE BIOSCIENCES INC (APS.CA) Stock News

APS.CA Latest News, Press Relases and Analysis